Use of azoximer bromide for treatment of children's inflammatory infections of respiratory system: a meta-analysis of controlled clinical studies
https://doi.org/10.22625/2072-6732-2019-11-4-31-41
Abstract
Objective. The aim of this meta-analysis is to summarize clinical efficacy of azoximer bromide for treatment of inflammatory respiratory infections in children and adolescents based on data from controlled clinical trials.
Materials and. methods. In total 5 clinical studies with data from 542 patients aged. 3—18 years were selected, where effectiveness of therapy with addition of azoximer bromide to combination, therapy was compared, to standard, symptomatic treatment.
Results. The results of the meta-analysis demonstrate that the addition of azoximer bromide from the first day to respiratory infections treatment in patients aged. 3-18 years helps to reduce temperature normalization, time [mean difference -1,92 day in favour of treatment with investigational drug (95% confidence interval 1,65; 1,15) according to the random effects model or -1,4 days (95% confidence interval 3,16; 0,67) according to fixed effects model]. Moreover azoximer bromide use in inflammatory respiratory infections treatment reduces the duration of fever and intoxication symptoms by 1,4 days in comparison with the control group (95% confidence interval 1,65; 1,15), headache by 0,53 days (95% confidence interval -0,91; -0,15), muscle and. joint pain by 1,59 days (95% confidence interval -2,1854; -1,0028) and catarrhal symptoms by 1,23 days (95% confidence interval 1,32; 1,14).
Conclusion. Addition of azoximer bromide as nosotropic therapeutic agent to combination, therapy of respiratory diseases make possible to control intoxication, symptoms in a better way, reduces the morbidity of infectious and inflammatory process, has positive effect on immune mechanisms and causes almost no side effects.
About the Authors
A. V. Karaulov
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
A. V. Gorelov
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
References
1. Letter of Federal Service on Customers' Rights Protection and Human Well-being Surveillance dated 20 June 2016. N 01/7783-16-27: "About outcome of 2015 — 2016 influenza and ARVI epidemic season". Moscow: Rospotrebnadzor [Federal Service on Customers' Rights Protection and Human Well-being Surveillance], 2016. (in Russian)
2. Letter of Federal Service on Customers' Rights Protection and Human Well-being Surveillance dated 9 June 2017. N 01/7567-17-27: "About outcome of 2016 — 2017 influenza and ARVI epidemic season". Moscow: Rospotrebnadzor [Federal Service on Customers' Rights Protection and Human Well-being Surveillance], 2017. (in Russian)
3. Selkova E.P., Grenkova T.A., Gudova N.V., Oranesyan A.S. Results on influenza and acute respiratory viral infection in the 2017—2018 epidemic seasons. Features of etiotropic therapy. Russkiy medicinskiy zhurnal. Meditsinskoye obozrenie. — 2018. — № 11. P. 49 — 53. (in Russian)
4. On the state sanitary and epidemiological welfare of the population in the Russian Federation in 2018: State report. Moscow: Rospotrebnadzor [Federal Service on Customers' Rights Protection and Human Well-being Surveillance], 2019. — 254 p. (in Russian) Available from: https://www.rospotrebnadzor.ru/upload/iblock/798/gosudarstvennyy-doklad-o-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naselenrya-v-rossiyskoy-federatsii-v-2018-godu.pdf
5. Cortjens B., van Woensel J.B.M., Bem R.A. Neutrophil Extracellular Traps in Respiratory Disease: guided anti-microbial traps or toxic webs? Paediatric Respiratory Reviews 21 (2017) 54—61
6. Brinkmann V, Reichard U, Goosmann C et al. Neutrophil extracellular traps kill bacteria. Science. 2004. —5;303(5663). — P. 1532-5.
7. Pinegin B.V., Dagil Yu.A., Vorobieva N.V., Pashchenkov М.В. Azoximer bromide effect on the neutrophil extracellular traps formation. Russkiy medicinskiy zhurnal. —2019. — №1(II). — P. 42-46. (in Russian)
8. Vavilovа V.P., Perevoschikova N.K. Rizo A.A. et al. The use of immunomodulator Polyoxidonium in therapy of children with pathology lymphopharyngeal ring. Allergologiya i immu-nologiya v pediatrii. — 2005. — №1 (4). — Р.47-53—4. (in Russian)
9. Vavilova V.P., Vavilov A.M., Cherkaeva A.Kh. The possibilities of modern treatment of acute respiratory viral infections in children. Consilium Medicum. Pediatriya. — 2015. — №3. — P. 76-81. (in Russian)
10. Kharit S.M., Galustyan A.N. Azoximer bromide is a safe and effective preparation for the treatment of acute respiratory infections of the upper respiratory tract in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of Phase II and III // Consilium Medicum. Pedi-atriya. — 2017. — №2. — P. 55-61. (in Russian)
11. Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A., & Song, F. (2000). Methods for meta-analysis in medical research. Chichester: John Wiley & Sons, Ltd.
12. Malanicheva T.G., Agafonova E. V. The effectiveness of immunomodulatory therapy of community-acquired pneumonia in frequently ill children. Detskie infektsii. — 2018. — №17(4). — P. 38-42. (in Russian)
13. Multicenter double-blind placebo-controlled randomized comparative clinical study to investigate efficacy and safety of use of 12 mg Polyoxidonium® tablets (LLC "NPO Petrovax Pharm") as part of combined therapy of acute upper respiratory infections of children aged 3-14 years: Clinical Study Report. Moscow Region: LLC "NPO Petrovax Pharm", 2008. — 342 pp. (in Russian)
14. Kharlamova F.S., Uchaykin V.F., Kuzmenko L.V. et al. Immunomodulatory agent Polyoxidonium for treatment of acute respiratory infections in children. Effektivnaya farma-koterapiya. — 2013. — №11. — P. 12-20. (in Russian)
15. Clinical study of safety and efficacy of Polyoxidonium tablets 12 mg for prophylaxis and treatment of recurrent upper respiratory tract diseases: clinical study report. Principal investigator Timchenko V.N. Saint Petersburg: Saint Petersburg State Pediatrics Medical Academy, 2008. — 14 pp. (in Russian)
16. Dudarev I.V., Sizyakina L.P. Dyuzhkov A.P. Efficacy of Polioxidonium in extracorporal therapy of sepsis in patients with congenital heart defects. Immunologiya. — 2002. — Vol. 23, №6. — P. 353-356. (in Russian)
17. Averkiev V.L. Tarasenko V.S. Latysheva T.V., Averkieva L.V. Correction of immunological disorders in patients with pancreonecrosis. Immunologiya. — 2002. — Vol. 23, №6. — P. 359-363. (in Russian)
18. Gordinskaya N.A. Pylaeva S.I. Sidorkin V.G., Aminev V.A. Impact of Polyoxidonium on the intoxication level in patients with burns. Immunologiya. — 2002. — Vol. 23, №6. — P. 363-365. (in Russian)
19. Ibragimova O.M., Alekseyeva L.A., Babachenko I.V., Bessonova T.V. Clinical and laboratory evaluation of intoxication syndrome in children with acute respiratory viral infections. Detskie infektsii. — 2014. — Vol. 13. № 2. — P. 61-63. (in Russian)
20. Medical Laboratory Technology: A Guide to Clinical Laboratory Diagnostics, Vol. 2., edited by A.I. Karpishchenko. Moscow: GEOTAR-Media, 2012. — 792 p. (in Russian)
Review
For citations:
Karaulov A.V., Gorelov A.V. Use of azoximer bromide for treatment of children's inflammatory infections of respiratory system: a meta-analysis of controlled clinical studies. Journal Infectology. 2019;11(4):31-41. (In Russ.) https://doi.org/10.22625/2072-6732-2019-11-4-31-41
Views:
2933
.png)
.png)
Email this article 